Burden of illness of bilateral neovascular age-related macular degeneration in Spain
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The burden of illness, including health resource utilization and costs associated with bilateral neovascular age-related macular degeneration (Nv-AMD), was assessed in Spain. PATIENTS AND METHODS: As part of an international prospective, case-controlled study, 89 Spanish patients with bilateral Nv-AMD were recruited by retina specialists and 96 Spanish control subjects were recruited by general practitioners and ophthalmologists. Physicians recorded clinical data and visual acuity (VA). In a subsequent telephone interview, Nv-AMD patients and controls completed the National Eye Institute Visual Function Questionnaire (NEI VFQ)-25, the EuroQol (EQ-5D), and the Hospital Anxiety and Depression Scale (HADS) questionnaire. Annual vision-related and non-vision-related medical costs and non-medical-related costs were calculated from study-specific questions. RESULTS: The mean age was 76.2 years for Nv-AMD patients and 61.9 years for control subjects. The adjusted mean (95% CI) NEI VFQ-25 summary score was 51.9 (48.5; 55.4) for Nv-AMD patients and 87.7 (85.5; 89.9) for control subjects (p<0.05). The summary score of Nv-AMD patients decreased significantly with VA declination. Mean direct vision-related medical and non-medical-related costs were significantly greater for Nv-AMD patients than the control subjects, whereas non-vision-related medical costs were similar between groups. The total mean annual resource utilization cost was euro5733 for Nv-AMD patients compared to euro1070 for control subjects (p<0.0001). CONCLUSIONS: Although the study design is subject to a number of limitations, patients with Nv-AMD in Spain have worse quality of life outcomes, greater depression, and higher healthcare costs as compared with similarly-aged individuals who are not affected by this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nine studies [34, 37–43, 45] reported direct non-medical costs per patient per annum, ranging from $688 to $15,418 (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [40]
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [40]
In the citing paper
“While annual direct non-medical costs were uniformly lower than direct medical costs in three studies [34, 39, 40] reporting both types of costs, they were higher in other cases [37, 41–43, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [40]
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959
A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population
Herrero, M. J., Blanch, J., Peri, J. M., De Pablo, J., Pintor, L., & Bulbena, A. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(03)00043-4 · Cited by 892
Visual Impairment and Falls in Older Adults: The Blue Mountains Eye Study
BOptom, R. Q. I., Cumming, R. G., Mitchell, P., & Attebo, K. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb01014.x · Cited by 734
Research works printed but not linked: 3
- Maguire MG, 1999, Natural history, 17
- Seddon JM, 2001, Retina, 1039
- SOIKOS, 2005, Base de datos de costes sanitarios. Version 2.2
Cited by
Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernández Alava, M., Mukuria, C., Rowen, D., Tosh, J., Tsuchiya, A., Evans, P., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18090 · Cited by 417
Taylor, D. J., Hobby, A. E., Binns, A. M., & Crabb, D. P. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011504 · Cited by 288
A Review of Generic Preference-Based Measures of Health-Related Quality of Life in Visual Disorders
Tosh, J. C., Brazier, J. E., Evans, P., & Longworth, L. (2011) · Value in Health · doi:10.1016/j.jval.2011.08.002 · Cited by 149
The economics of vision impairment and its leading causes: A systematic review
Marques, A. P., Ramke, J., Cairns, J., Butt, T., Zhang, J. H., Jones, I., Jovic, M., Nandakumar, A., Faal, H., Taylor, H., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101354 · Cited by 137
Eramudugolla, R., Wood, J. M., & Anstey, K. J. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00056 · Cited by 122
Dawson, S. R., Mallen, C. D., Gouldstone, M. B., Yarham, R., & Mansell, G. (2014) · BMC Ophthalmology · doi:10.1186/1471-2415-14-78 · Cited by 117
Comparison of Scoring Approaches for the NEI VFQ‐25 in Low Vision
Dougherty, B. E., & Bullimore, M. A. (2010) · Optometry and Vision Science · doi:10.1097/opx.0b013e3181e61bd8 · Cited by 55
Loftus, J., Sultan, M. B., & Pleil, A. M. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7613 · Cited by 47
The economic and humanistic burden of patients in receipt of current available therapies for nAMD
Jaffe, D. H., Chan, W. W., Bezlyak, V., & Skelly, A. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0058 · Cited by 40
Rossouw, P., Guichard, M.-M., & Hatz, K. B. (2020) · Ophthalmic and Physiological Optics · doi:10.1111/opo.12736 · Cited by 23
Pablo, L., Garay‐Aramburu, G., García‐Layana, A., Fernandez, A., Vázquez, I., Acebes, X., Zulueta, J., Balonga, D., Salinas-Ortega, L., Muñoz, Á., et al. (2024) · Health Economics Review · doi:10.1186/s13561-024-00546-y · Cited by 17
Haig, J., Barbeau, M., & Ferreira, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1154566 · Cited by 16
Tabano, D. C., Watane, A., Gale, R. P., Cox, O., Hill, S., Longworth, L., Oluboyede, Y., Ahmed, A. M., & Patel, N. A. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01180-5 · Cited by 15
Costes en pacientes miopes magnos con y sin neovascularización coroidea miópica
Ruiz‐Moreno, J. M., & Roura, M. (2016) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2016.01.013 · Cited by 10
Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain
Abraldes, M. J., Calvo, P., Gámez Lechuga, M., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Ruiz-Moreno, J. M. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-00960-9 · Cited by 6
Cost of myopic patients with and without myopic choroidal neovascularisation
Ruiz-Moreno, J. M., & Roura, M. (2016) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2016.04.015 · Cited by 6
Visual function analysis in acute posterior vitreous detachment
Schweitzer, K. D., Eneh, A. A., Hurst, J., Bona, M. D., Rahim, K. J., & Sharma, S. (2011) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2011.05.010 · Cited by 6
Kato, A., Yasukawa, T., Sugita, I., Yoshida, M., Nozaki, M., Hirano, Y., Kondo, J., Abe, T., Sugita, K., Okita, T., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02052-1 · Cited by 5
Rates of Comorbid Anxiety and Depression in Patients With Age-Related Macular Degeneration
Olson, D., Zhang, X., Ward, M. F., Le, P. H., Ismail, O. M., Poole, Z. B., Donaldson, J. C., Buren, E. C. V., Lin, F., Ulrich, J., et al. (2019) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419849199 · Cited by 5
Tran, E., Maher, A., Basilious, A., & Malvankar‐Mehta, M. S. (2025) · Archives of Mental Health · doi:10.4103/amh.amh_80_24 · Cited by 4
Gibbert, J., Müller, D., Fauser, S., & Stock, S. (2013) · Der Ophthalmologe · doi:10.1007/s00347-012-2750-5 · Cited by 4
Rowen, D., Carlton, J., Terheyden, J. H., Finger, R. P., Wickramasekera, N., Brazier, J. E., Agostini, H. T., Altay, L., Atia, R., Bandello, F. M., et al. (2024) · Value in Health · doi:10.1016/j.jval.2024.02.001 · Cited by 4
Kim, G., Kim, J. H., Chang, Y. S., Kim, J. W., Kim, C. G., & Lee, D. W. (2017) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2017.58.1.62 · Cited by 4
Influence of new societal factors on neovascular age-related macular degeneration outcomes
Giocanti‐Auregan, A., Chbat, E., Darugar, A., Morel, C., Morin, B., Conrath, J., & Devin, F. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0690-9 · Cited by 4
Kabedi, N. N., Kayembe, D. L., & Mwanza, J.-C. (2020) · Seminars in Ophthalmology · doi:10.1080/08820538.2020.1774623 · Cited by 3
Rowen, D., Carlton, J., McDool, E., Holz, F. G., Zakaria, N., Terheyden, J. H., Finger, R. P., Agostini, H., Aires, I. D., Altay, L., et al. (2025) · Value in Health · doi:10.1016/j.jval.2025.04.2155 · Cited by 2
Carga económica de la degeneración macular neovascular y el edema macular diabético en Colombia
Gil-Rojas, Y., Amaya-Granados, D., Sardi, C., Robles, A., & Hernández, F. (2023) · Revista Sociedad Colombiana de Oftalmología · doi:10.24875/rsco.23000015 · Cited by 2
Coco, R. M., Sanabria, M. R., Fernández, I., Sala, A. B., Valverde, C., & Perez, R. (2013) · Journal of Hospital Administration · doi:10.5430/jha.v2n4p37 · Cited by 2
López‐Miguel, A., Coco-Martín, M. B., Martínez-Fernández, R., Gómez-Ramírez, A. M., García‐Ayuso, D., Sobrado‐Calvo, P., & Maldonado, M. J. (2013) · Ophthalmologica · doi:10.1159/000351652 · Cited by 1
Anxiety in Patients with Neovascular Age-related Macular Degeneration
Weinstein, O., Cohen, A. D., Levy, J., Zloto, O., Freud, T., Krieger, I., Comaneshter, D. S., & Shemesh, R. (2022) · Ophthalmic Epidemiology · doi:10.1080/09286586.2022.2090007 · Cited by 1
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
Hermosilla, A. M. G., Esteban-González, E., Díaz-Granda, M. J., & Rodríguez-de-la-Rúa-Franch, E. (2016) · Revista Mexicana de Oftalmología · doi:10.1016/j.mexoft.2016.02.001
Bevacizumab and Cataract Surgery in AMD
Amat-Peral, P., Ruiz‐Moreno, J. M., Montero, J. A., & Lugo, F. L. (2012) · Highlights of Ophthalmology · doi:10.5005/hoo-10101-40105
Lee, H. C., Nam, H., Kang, D., & Yeom, M. I. (2021) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2021.62.8.1069
ปัจจัยที่มีความสัมพันธ์กับคุณภาพชีวิตด้านการมองเห็นของผู้สูงอายุโรคต้อหิน
จันทรรัตน์, ภ., & ชูวรรธนะปกรณ์, ท. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.1105
ปัจจัยที่สัมพันธ์กับคุณภาพชีวิตด้านสุขภาพของผู้สูงอายุที่มีจอตาเสื่อมจากอายุ
พูนเปี่ยม, ก., & สาสัตย์, ศ. (2015) · Chula Digiverse · doi:10.58837/chula.the.2015.514
Associations Between Age-Related Eye Diseases and Mental Health Conditions
Yu, H.-N., & Ying, G. (2026) · Ophthalmic Epidemiology · doi:10.1080/09286586.2026.2675294
Metadata
- Authors
- María Ruiz-Moreno, J., María Coco, R., García-Arumí, J., Xu, X., & Zlateva, G.
- Affiliations
- University of Castilla La Mancha, Albacete, Spain
- Instituto de Oftalmobiología Aplicada (IOBA), Universidad de Valladolid, Valladolid, Spain
- Hospital Vall d’Hebrón, Barcelona, Spain
- Covance Market Access Services Inc, Gaithersburg, Maryland, USA
- Pfizer (United States) (US)
- ORCID
- Xu, Xiao
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2006-06-10
- Volume
- 24
- Issue
- 7
- Pages
- 2103-2111
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2017089824
- Cited by
- 36
- References
- 24
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 5 · 2014: 2 · 2013: 4 · 2012: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, bilateral disease, disease burden, quality of life, visual function, visual acuity loss, health care costs, health resource utilization, depression, anxiety, Spain
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Interviews as Topic, Macular Degeneration, Male, Middle Aged, Quality of Life, Spain, Visual Acuity, Case-Control Studies, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.